Demographics and disease characteristics of patients with psoriasis enrolled in theBritishAssociation ofDermatologistsBiologicInterventionsRegister
British Journal of Dermatology2015Vol. 173(2), pp. 510–518
Citations Over TimeTop 10% of 2015 papers
Ireny Iskandar, Darren M. Ashcroft, Richard B. Warren, Zenas Z N Yiu, Kathleen McElhone, Mark Lunt, Juliet N. Barker, A. David Burden, Anthony D. Ormerod, Nick J. Reynolds, Catherine Smith, C.E.M. Griffiths
Abstract
BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.
Related Papers
- → Serum Levels of IL-17 and IL-22 Are Reduced by Etanercept, but not by Acitretin, in Patients with Psoriasis: a Randomized-Controlled Trial(2008)178 cited
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited
- → PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis(2011)1 cited